Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Pharmacological decrease of liver stiffness is pressure-related and predicts long-term clinical outcome.

Piecha F, Mandorfer M, Peccerella T, Ozga AK, Poth T, Vonbank A, Seitz HK, Rausch V, Reiberger T, Mueller S.

Am J Physiol Gastrointest Liver Physiol. 2018 Oct 1;315(4):G484-G494. doi: 10.1152/ajpgi.00392.2017. Epub 2018 May 10.

PMID:
29746172
2.

Shear-wave elastography: a noninvasive tool for monitoring changing hepatic venous pressure gradients in patients with cirrhosis.

Choi SY, Jeong WK, Kim Y, Kim J, Kim TY, Sohn JH.

Radiology. 2014 Dec;273(3):917-26. doi: 10.1148/radiol.14140008. Epub 2014 Jul 14.

PMID:
25025464
3.

Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.

Reiberger T, Ferlitsch A, Payer BA, Pinter M, Homoncik M, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab.

J Gastroenterol. 2012 May;47(5):561-8. doi: 10.1007/s00535-011-0517-4. Epub 2011 Dec 15.

PMID:
22170417
4.

A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients.

Castaño G, Viudez P, Riccitelli M, Sookoian S.

Ann Hepatol. 2003 Jan-Mar;2(1):36-40.

PMID:
15094704
5.

Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease.

Agasti AK, Mahajan AU, Phadke AY, Nathani PJ, Sawant P.

J Dig Dis. 2013 May;14(5):266-71. doi: 10.1111/1751-2980.12025.

PMID:
23280243
6.

Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study.

Robic MA, Procopet B, Métivier S, Péron JM, Selves J, Vinel JP, Bureau C.

J Hepatol. 2011 Nov;55(5):1017-24. doi: 10.1016/j.jhep.2011.01.051. Epub 2011 Feb 25.

PMID:
21354450
7.

Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease.

Bureau C, Metivier S, Peron JM, Selves J, Robic MA, Gourraud PA, Rouquet O, Dupuis E, Alric L, Vinel JP.

Aliment Pharmacol Ther. 2008 Jun;27(12):1261-8. doi: 10.1111/j.1365-2036.2008.03701.x. Epub 2008 Apr 4.

8.

Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study.

Schepis F, Vukotic R, Berzigotti A, Carrión JA, Forns X, Abraldes JG, García-Valdecasas JC, Navasa M, García-Pagán JC, Bosch J.

Liver Transpl. 2013 Apr;19(4):450-6. doi: 10.1002/lt.23614. Epub 2013 Mar 20.

9.

Evaluation of liver fibrosis and hepatic venous pressure gradient with MR elastography in a novel swine model of cirrhosis.

Huang SY, Abdelsalam ME, Harmoush S, Ensor JE, Chetta JA, Hwang KP, Stafford RJ, Madoff DC, Avritscher R.

J Magn Reson Imaging. 2014 Mar;39(3):590-7. doi: 10.1002/jmri.24189. Epub 2013 Nov 7.

PMID:
24532376
10.

Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis.

González-Abraldes J, Albillos A, Bañares R, Del Arbol LR, Moitinho E, Rodríguez C, González M, Escorsell A, García-Pagán JC, Bosch J.

Gastroenterology. 2001 Aug;121(2):382-8.

PMID:
11487547
11.

Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study.

Colecchia A, Colli A, Casazza G, Mandolesi D, Schiumerini R, Reggiani LB, Marasco G, Taddia M, Lisotti A, Mazzella G, Di Biase AR, Golfieri R, Pinzani M, Festi D.

J Hepatol. 2014 Jun;60(6):1158-64. doi: 10.1016/j.jhep.2014.02.024. Epub 2014 Mar 6.

PMID:
24607624
12.

Combined effect of hepatic venous pressure gradient and liver stiffness on long-term mortality in patients with cirrhosis.

Lee JG, Sohn JH, Jeong JY, Kim TY, Kim SM, Cho YS, Kim Y.

Korean J Intern Med. 2019 Feb 25. doi: 10.3904/kjim.2018.151. [Epub ahead of print]

13.

Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors.

Llop E, Berzigotti A, Reig M, Erice E, Reverter E, Seijo S, Abraldes JG, Bruix J, Bosch J, García-Pagan JC.

J Hepatol. 2012 Jan;56(1):103-8. doi: 10.1016/j.jhep.2011.06.027. Epub 2011 Aug 7.

PMID:
21827733
14.
15.

Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.

Tripathi DM, Erice E, Lafoz E, García-Calderó H, Sarin SK, Bosch J, Gracia-Sancho J, García-Pagán JC.

Am J Physiol Gastrointest Liver Physiol. 2015 Sep 1;309(5):G301-9. doi: 10.1152/ajpgi.00010.2015. Epub 2015 Jul 2.

16.

Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function.

Albillos A, Lledó JL, Rossi I, Pérez-Páramo M, Tabuenca MJ, Bañares R, Iborra J, Garrido A, Escartín P, Bosch J.

Gastroenterology. 1995 Oct;109(4):1257-65.

PMID:
7557093
17.

Short-term effects of propranolol on portal venous pressure.

Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJ, Morse SS, Alberts JL.

Hepatology. 1986 Jan-Feb;6(1):101-6.

PMID:
3943775
18.

Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.

Bañares R, Moitinho E, Piqueras B, Casado M, García-Pagán JC, de Diego A, Bosch J.

Hepatology. 1999 Jul;30(1):79-83.

PMID:
10385642
19.

Hemodynamic Response to Carvedilol is Maintained for Long Periods and Leads to Better Clinical Outcome in Cirrhosis: A Prospective Study.

Kirnake V, Arora A, Gupta V, Sharma P, Singla V, Bansal N, Goyal M, Chawlani R, Kumar A.

J Clin Exp Hepatol. 2016 Sep;6(3):175-185. Epub 2016 Jan 23.

20.

Propranolol plus molsidomine vs propranolol alone in the treatment of portal hypertension in patients with cirrhosis.

García-Pagán JC, Escorsell A, Feu F, Bandi JC, Moitinho E, Casado M, Bosch J, Rodés J.

J Hepatol. 1996 Apr;24(4):430-5.

PMID:
8738729

Supplemental Content

Support Center